Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sarecycline - Almirall S.A./Paratek Pharmaceuticals

Next Previous
Drug Profile

Sarecycline - Almirall S.A./Paratek Pharmaceuticals

Alternative Names: P 0005672; P 005672; Seysara; WC-3035

Latest Information Update: 06 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Paratek Pharmaceuticals
  • Developer Actavis; Almirall S.A.; Paratek Pharmaceuticals
  • Class Amides; Antiacnes; Antibacterials; Naphthacenes; Skin disorder therapies; Small molecules; Tetracyclines; Vascular disorder therapies
  • Mechanism of Action Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acne vulgaris
  • Discontinued Rosacea

Most Recent Events

  • 24 Feb 2025 Almirall S.A. anticipates regulatory approval for Acne vulgaris in China in the second half of 2025
  • 16 Dec 2024 Apotex and Almirall enters into an exclusive agreement to market and distribute Sarecycline for Acne in Canada
  • 30 Sep 2023 Preregistration for Acne vulgaris in China (PO) (Almirall S.A. pipeline, November 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top